Evidence map›Paper›PMID 33887217›Full record

ArticleThe American journal of pathology2021

Divergent Regulation of Alveolar Type 2 Cell and Fibroblast Apoptosis by Plasminogen Activator Inhibitor 1 in Lung Fibrosis.

Chunsun Jiang, Gang Liu, Lu Cai, Jessy Deshane, Veena Antony, Victor J Thannickal, Rui-Ming Liu

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Endothelial HRedox biology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Wnt5a/β-catenin axis is involved in the downregulation of AT2 lineage by PAI-1.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chunsun JiangDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Gang LiuDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Lu CaiPediatric Research Institute, Department of Pediatrics of the University of Louisville School of Medicine, Louisville, Kentucky.
Jessy DeshaneDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Veena AntonyDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Victor J ThannickalDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Rui-Ming LiuDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: rliu@uab.edu.
University of Alabama at Birmingham · USUniversity of Louisville · US

Funding

Therapeutic Targeting of the Myofibroblast in Fibrotic Lung DiseaseP01HL114470 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI THANNICKAL, VICTOR J. · 2013 to 2022
$17.8M
Program on cellular metabolism and lung fibrosisR35HL135830 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, GANG · 2017 to 2023
$5.2M
Glutathione and Lung FibrosisR01HL088141 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, RUI-MING · 2008 to 2011
$1.4M
PAI-1 and aging-related susceptibility to lung fibrosisR56HL131054 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, RUI-MING · 2016 to 2016
$438k
NHLBI NIH HHS P01 HL114470NHLBI NIH HHS R01 HL088141NHLBI NIH HHS R35 HL135830NHLBI NIH HHS R56 HL131054
6 · The paper itself

Abstract

Increased apoptosis sensitivity of alveolar type 2 (ATII) cells and increased apoptosis resistance of (myo)fibroblasts, the apoptosis paradox, contributes to the pathogenesis of idiopathic pulmonary fibrosis (IPF). The mechanism underlying the apoptosis paradox in IPF lungs, however, is unclear. Aging is the greatest risk factor for IPF. In this study, we show, for the first time, that ATII cells from old mice are more sensitive, whereas fibroblasts from old mice are more resistant, to apoptotic challenges, compared with the corresponding cells from young mice. The expression of plasminogen activator inhibitor 1 (PAI-1), an important profibrogenic mediator, was significantly increased in both ATII cells and lung fibroblasts from aged mice. In vitro studies using PAI-1 siRNA and active PAI-1 protein indicated that PAI-1 promoted ATII cell apoptosis but protected fibroblasts from apoptosis, likely through dichotomous regulation of p53 expression. Deletion of PAI-1 in adult mice led to a reduction in p53, p21, and Bax protein expression, as well as apoptosis sensitivity in ATII cells, and their increase in the lung fibroblasts, as indicated by in vivo studies. This increase was associated with an attenuation of lung fibrosis after bleomycin challenge. Since PAI-1 is up-regulated in both ATII cells and fibroblasts in IPF, the results suggest that increased PAI-1 may underlie the apoptosis paradox of ATII cells and fibroblasts in IPF lungs.

Indexed as

Age FactorsAlveolar Epithelial CellsAnimalsApoptosisFibroblastsIdiopathic Pulmonary FibrosisMicePlasminogen Activator Inhibitor 1Plasminogen Activator Inhibitor 1

Identifiers

PMID33887217
PMCPMC8351125
OpenAlexW3153177261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.